All data are based on the daily closing price as of November 18, 2026
m

Medy-Tox

086900.KQ
52.71 USD
-0.28
-0.53%

Overview

Last close
52.71 usd
Market cap
340.42M usd
52 week high
131.45 usd
52 week low
46.23 usd
Target price
64.15 usd

Valuation

P/E
31.6969
Forward P/E
21.5983
Price/Sales
1.7748
Price/Book Value
1.2142
Enterprise Value
399.12M usd
EV/Revenue
2.1161
EV/EBITDA
70.1378

Key financials

Revenue TTM
188.61M usd
Gross Profit TTM
116.43M usd
EBITDA TTM
27.90M usd
Earnings per Share
1.67 usd
Dividend
0.9 usd
Total assets
369.54M usd
Net debt
48.91M usd

About

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.
  • Symbol
    086900.KQ
  • Exchange
    KQ
  • Isin
    KR7086900008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Hyun-Ho Jung
  • Headquarter
    Cheongju
  • Web site
    https://www.medytox.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top